Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial EQUATE

What's the purpose of this trial?

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone).

This trial is currently open and accepting patients.


What will happen during the trial?

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

  • STEP 0 - Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2 (PS 3 allowed if secondary to pain)
  • STEP 0 - Patient must have newly diagnosed multiple myeloma (MM) by International Myeloma Working Group (IMWG) criteria
  • STEP 0 - Patient must agree to register to the mandatory REVLIMID Risk Evaluation and Mitigation Strategy (RevREMS) program and be willing and able to comply with the requirements of RevREMS
  • STEP 0 - Patient must be able to undergo diagnostic bone marrow aspirate following preregistration.

    • NOTE: Bone marrow aspirate specimen must be submitted to Adaptive Biotechnologies for clonoSEQ Assay
    • NOTE: Adaptive Biotechnologies will release results to the diagnostic Portal from the Clonality (ID) test within fourteen (14) days of receipt and reconciliation of fresh bone marrow specimen to the submitting institution
  • STEP 1 - Patient must meet all eligibility criteria in STEP 0 with exception of allergy requirement
  • STEP 1 - Institution must have received the Clonality (ID) test results from Adaptive Biotechnologies and dominant sequences were identified
  • STEP 1 - Patient must have standard risk MM as defined by the Revised International Staging System (RISS) stage I or II
    • NOTE: R-ISS stage is based on serum beta2 microglobulin, albumin and lactate dehydrogenase (LDH) levels along with presence of chromosomal abnormalities (CA) detected by interphase fluorescent in situ hybridization (iFISH). Presence of del(17p), t(4;14), and/or t(14;16) is considered high risk and absence of these, including any other findings, are standard risk
    • R-ISS stage
      • Stage I: ISS stage I [beta2 macroglobulin < 3.5 mg/L, albumin > 3.5 g/dL] AND standard-risk CA AND normal LDH
      • Stage II: Not R-ISS stage I or III
      • Stage III: ISS stage III [beta2 macroglobulin > 5.5 mg/L] AND high-risk CA OR high LDH (> upper limit of normal) [patients with stage III are ineligible]
  • STEP 1 - Patient must have measurable or evaluable disease as defined by having one or more of the following, obtained within 28 days prior to registration:

    • >= 1 g/dL monoclonal protein (M-protein) on serum protein electrophoresis
    • >= 200 mg/24 hours of monoclonal protein on a 24-hour urine protein electrophoresis
    • Involved free light chain >= 10 mg/dL or >= 100 mg/L AND abnormal serum immunoglobulin kappa to lambda free light chain ratio (< 0.26 or > 1.65)
    • Monoclonal bone marrow plasmacytosis >= 30% (evaluable disease)
  • STEP 1 - Patients must have a serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), and serum free light chain (FLC) assay performed within 28 days prior to registration. In addition, a bone marrow biopsy and/or aspirate is required within 28 days if bone marrow is being followed for response

    • NOTE: UPEP (on a 24-hour collection) is required, no substitute method is acceptable. Urine must be followed monthly if the baseline urine M-spike is >= 200 mg/24 hr. Please note that if both serum and urine M-components are present, both must be followed in order to evaluate response
    • NOTE: The serum free light chain test is required to be done if the patient does not have measurable disease in the serum or urine. Measurable disease in the serum is defined as having a serum M-spike >= 1 g/dL. Measurable disease in the urine is defined as having a urine M-spike >= 200 mg/24 hr
  • STEP 1 - Calculated creatinine clearance > 30 mL/min (obtained =< 14 days prior to Step 1 registration)
  • STEP 1 - Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained =< 14 days prior to Step 1 registration)
  • STEP 1 - Untransfused platelet count >= 75,000/mm^3 (obtained =< 14 days prior to Step 1 registration)
  • STEP 1 - Hemoglobin >= 8.0 g/dL (obtained =< 14 days prior to Step 1 registration)
  • STEP 1 - Total bilirubin =< 1.5 x ULN (institutional upper limit of normal) (obtained =< 14 days prior to Step 1 registration)
  • STEP 1 - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (obtained =< 14 days prior to Step 1 registration)
  • STEP 1 - Patient must have received no more than one cycle (28 days or less) of prior chemotherapy and no more than 160 mg of prior dexamethasone (or equivalent dose of prednisone) for treatment of symptomatic myeloma. Patient must not have been exposed to daratumumab for treatment of symptomatic myeloma. Prior radiation therapy to symptomatic lesions is allowed provided there are no residual toxicity related to radiation and blood counts meet the study requirements. Radiation treatment must be completed at least 14 days prior to Step 1 registration
  • STEP 1 - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial
  • STEP 1 - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • STEP 1 - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • STEP 1 - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
  • STEP 1 - Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. Patients must not have evidence of current uncontrolled cardiovascular conditions, including hypertension, cardiac arrhythmias, congestive heart failure, unstable angina, or myocardial infarction within 6 months prior to Step 1 registration
  • STEP 1 - Patient may have a history of current or previous deep vein thrombosis (DVT) or pulmonary embolism (PE) but must be willing to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation
  • STEP 1 - Patients with a history of chronic obstructive pulmonary disease (COPD) must have FEV1 testing done within 28 days prior to Step 1 registration and the forced expiratory volume in 1 second (FEV1) must be > 50% of predicted normal
  • STEP 2 - Institution must have received Tracking (MRD) test results from Adaptive Biotechnologies
  • STEP 2 - Patient must have completed the Step 1 Induction phase of this protocol without experiencing progression
  • STEP 2 - Patient must be registered to Step 2 within 8 weeks of completing Step 1 Induction Treatment, counting from last day of completion of last cycle
  • STEP 2 - Patient must have an ECOG performance status (PS) of 0-2 (PS 3 allowed if secondary to pain)
  • STEP 2 - Any adverse event(s) related to Step 1 Induction Treatment must have resolved to grade 2 or less
  • STEP 2 - Hemoglobin >= 8 g/dL (obtained within 14 days prior to Step 2 randomization)
  • STEP 2 - Platelet count >= 50,000/mm^3 (obtained within 14 days prior to Step 2 randomization)
  • STEP 2 - Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained within 14 days prior to Step 2 randomization)
  • STEP 2 - Calculated creatinine clearance >= 30 mL/min (obtained within 14 days prior to Step 2 randomization)
  • STEP 2 - Total bilirubin =< 1.5 x ULN (Institutional upper limit of normal) (obtained within 14 days prior to Step 2 randomization)
  • STEP 2 - ALT and AST < 3 x ULN (obtained within 14 days prior to Step 2 randomization)

Exclusion Criteria:

  • STEP 0 - Patient must not have any known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or Investigator's Brochure), or known sensitivity to mammalian-derived products
  • STEP 1 - Women must not be pregnant or breast-feeding due to the potential harm and teratogenic effects to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All females of childbearing potential must have a blood test or urine study with a sensitivity of at least 25 mIU/mL within 10-14 days prior to Step 1 registration to rule out pregnancy and again within 24 hours prior to the first dose of lenalidomide. Females of childbearing potential must also agree to ongoing pregnancy testing while on protocol treatment. A female of childbearing potential is defined as any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:

    • Has achieved menarche at some point,
    • Has not undergone a hysterectomy or bilateral oophorectomy; or
    • Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  • STEP 1 - Women of childbearing potential must not expect to conceive children by using accepted and effective method(s) of contraception (for this protocol defined as the use of TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME for 1) at least 28 days before starting protocol treatment; 2) while participating in the study; 3) during dose interruptions; and 4) for at least 3 months days after the last dose of protocol treatment) OR by practicing true abstinence from sexual intercourse for the duration of their participation in the study (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception). Men must not expect to father children by practicing true abstinence from sexual intercourse for the duration of their participation in the study (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception) OR use a latex condom during sexual contact with a female of child bearing potential while participating in the study and for at least 3 months after the last dose of protocol treatment even if they have had a successful vasectomy. Men must also agree to abstain from donating sperm while on study treatment and for 3 months after the last dose of protocol treatment even if they have had a successful vasectomy. Both women and men must both agree to abstain from donating blood during study participation and for at least 28 days after the last dose of protocol treatment
  • STEP 1 - Patient must not have peripheral neuropathy >= grade 2 on clinical examination or grade 1 with pain at time of Step 1 registration
  • STEP 1 - Patient must not have any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol
  • STEP 1 - Patient must not have moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification

    • NOTE: Patients who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to register
  • STEP 1 - Patient must not receive any other concurrent chemotherapy, or any ancillary therapy considered investigational while on this protocol

    • NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment
  • STEP 2 - Patient must not have received any non-protocol therapy outside of the assigned Step 1 Induction treatment including stem cell transplant
  • STEP 2 - Women must not be pregnant or breast-feeding due to the potential harm and teratogenic effects to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All females of childbearing potential must have a blood test or urine study with a sensitivity of at least 25 mIU/mL within 10-14 days prior to Step 2 randomization to rule out pregnancy and again within 24 hours prior to the first dose of lenalidomide. Females of childbearing potential must also agree to ongoing pregnancy testing while on protocol treatment. A female of childbearing potential is defined as any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:

    • Has achieved menarche at some point,
    • Has not undergone a hysterectomy or bilateral oophorectomy; or
    • Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
  • STEP 2 - Women of childbearing potential must not expect to conceive children by using accepted and effective method(s) of contraception (for this protocol defined as the use of TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME for 1) at least 28 days before starting protocol treatment; 2) while participating in the study; 3) during dose interruptions; and 4) for at least 3 months days after the last dose of protocol treatment) OR by practicing true abstinence from sexual intercourse for the duration of their participation in the study (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception).

Men must not expect to father children by practicing true abstinence from sexual intercourse for the duration of their participation in the study (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception) OR use a latex condom during sexual contact with a female of child bearing potential while participating in the study and for at least 3 months after the last dose of protocol treatment even if they have had a successful vasectomy. Men must also agree to abstain from donating sperm while on study treatment and for 3 months after the last dose of protocol treatment even if they have had a successful vasectomy. Both women and men must both agree to abstain from donating blood during study participation and for at least 28 days after the last dose of protocol treatment


Additional Trial Information

Phase 3

Enrollment: 1,450 patients (estimated)

View More

Trial Locations

This clinical trial is not limited to the sites that you find listed below. If you are a patient and do not see your center listed as a participating site below, please contact SparkCures at (888) 828-2206 for additional assistance.

All Trial Locations

View all clinical trial locations sorted by state.

Alaska

Anchorage Oncology Centre

Anchorage, AK

Temporarily Suspended

Katmai Oncology Group

Anchorage, AK

Open and Accepting

Providence Alaska Medical Center

Anchorage, AK

Open and Accepting

Alaska Women's Cancer Care

Anchorage, AK

Open and Accepting

Alaska Oncology and Hematology LLC

Anchorage, AK

Open and Accepting

Alaska Breast Care and Surgery LLC

Anchorage, AK

Open and Accepting

Anchorage Radiation Therapy Center

Anchorage, AK

Open and Accepting

Anchorage Associates in Radiation Medicine

Anchorage, AK

Open and Accepting

Arizona

Cancer Center at St. Joseph's

Phoenix, AZ

Open and Accepting

University of Arizona Cancer Center

Tucson, AZ

Open and Accepting

Banner Health University Medical Center

Tucson, AZ

Open and Accepting

Arizona Oncology - Rudasill Tucson - Rudasill - Medical Oncology

Tucson, AZ

Open and Accepting

Arkansas

Mercy Hospital Fort Smith

Fort Smith, AR

Open and Accepting

CHI St. Vincent Hot Springs Cancer Center

Hot Springs, AR

Temporarily Suspended

CARTI Cancer Center

Little Rock, AR

Open and Accepting

Central Arkansas Veterans Healthcare System VA Central Arkansas

Little Rock, AR

Temporarily Suspended

California

Dignity Health Mission Hope Cancer Center - Arroyo Grande

Arroyo Grande, CA

Open and Accepting

Sutter Auburn Faith Hospital

Auburn, CA

Open and Accepting

Alta Bates Cancer Care Center

Berkeley, CA

Open and Accepting

Mercy Cancer Center Mercy San Juan Medical Center

Carmichael, CA

Open and Accepting

Sutter Davis Hospital

Davis, CA

Open and Accepting

Mercy Cancer Center - Elk Grove

Elk Grove, CA

Open and Accepting

Palo Alto Medical Foundation (Mountain View)

Mountain View, CA

Open and Accepting

Sutter Cancer Research Consortium

Novato, CA

Open and Accepting

Palo Alto Medical Foundation - Sutter Cancer Research Consortium

Palo Alto, CA

Open and Accepting

Mercy Cancer Center - Rocklin

Rocklin, CA

Open and Accepting

Sutter Health Medical Foundation - Roseville

Roseville, CA

Open and Accepting

Mercy Cancer Center

Sacramento, CA

Open and Accepting

Sutter General Hospital - Sacramento - Sutter Cancer Research Consortium

Sacramento, CA

Open and Accepting

Sutter Health California Pacific Medical Center (Webster)

San Francisco, CA

Open and Accepting

Sutter Cancer Research Consortium - Santa Cruz

Santa Cruz, CA

Open and Accepting

Mission Hope Cancer Center (Santa Maria) Central Coast Medical Oncology

Santa Maria, CA

Open and Accepting

Sutter Cancer Research Consortium - Sutter Pacific Medical Foundation

Santa Rosa, CA

Open and Accepting

Sutter Cancer Research Consortium - Sunnyvale Center

Sunnyvale, CA

Open and Accepting

Sutter Solano Cancer Center

Vallejo, CA

Open and Accepting

Woodland Memorial Hospital

Woodland, CA

Open and Accepting

Colorado

Littleton Adventist Hospital

Centennial, CO

Temporarily Suspended

Centura Penrose Hospital

Colorado Springs, CO

Open and Accepting

Rocky Mountain Cancer Center - Penrose Hospital Colorado Springs

Colorado Springs, CO

Open and Accepting

St. Francis Medical Center Catholic Health Initiatives

Colorado Springs, CO

Open and Accepting

Porter Adventist Hospital

Denver, CO

Temporarily Suspended

Centura Mercy Hospital

Durango, CO

Open and Accepting

Centura Southwest Oncology

Durango, CO

Open and Accepting

Centura St. Anthony Hospital

Lakewood, CO

Open and Accepting

Centura Longmont United Hospital

Longmont, CO

Open and Accepting

Rocky Mountain Cancer Centers (Longmont) Longmont

Longmont, CO

Temporarily Suspended

Centura Parker Adventist Hospital

Parker, CO

Temporarily Suspended

Saint Mary Corwin Medical Center

Pueblo, CO

Open and Accepting

Connecticut

Smilow Cancer Hospital The Center for Cancer Care at Griffin Hospital

Derby, CT

Open and Accepting

Smilow Cancer Hospital

Fairfield, CT

Open and Accepting

Smilow Cancer Hospital Saint Francis Hospital

Glastonbury, CT

Open and Accepting

Smilow Cancer Hospital

Greenwich, CT

Open and Accepting

Smilow Cancer Hospital Shoreline Medical Center

Guilford, CT

Open and Accepting

Hartford Hospital

Hartford, CT

Open and Accepting

Midstate Medical Center

Meriden, CT

Open and Accepting

The Hartford HealthCare Cancer Institute The Hospital of Central Connecticut

New Britain, CT

Open and Accepting

Smilow Cancer Hospital at Yale New Haven

New Haven, CT

Open and Accepting

North Haven Medical Center Yale-New Haven Hospital

North Haven, CT

Open and Accepting

Smilow Cancer Hospital Yale New Haven Health

Orange, CT

Open and Accepting

Smilow Cancer Hospital

Torrington, CT

Open and Accepting

Smilow Cancer Hospital Park Avenue Medical Center

Trumbull, CT

Open and Accepting

Smilow Cancer Hospital The Harold Leever Regional Cancer Center

Waterbury, CT

Open and Accepting

Smilow Cancer Hospital L+M Waterford Cancer Care Center

Waterford, CT

Open and Accepting

Delaware

ChristianaCare Hematology

Newark, DE

Open and Accepting

ChristianaCare Helen F. Graham Cancer Center Christiana Hospital

Newark, DE

Open and Accepting

Nanticoke Memorial Hospital

Seaford, DE

Temporarily Suspended

Florida

Holy Cross Hospital

Fort Lauderdale, FL

Open and Accepting

Sacred Heart Medical Oncology Group

Pensacola, FL

Open and Accepting

Saint Mary's Hospital

West Palm Beach, FL

Open and Accepting

Georgia

Grady Memorial Hospital

Atlanta, GA

Open and Accepting

Idaho

Saint Alphonsus Cancer Care Center (Boise)

Boise City, ID

Open and Accepting

Saint Alphonsus Cancer Care Center (Caldwell)

Caldwell, ID

Open and Accepting

Kootenai Clinic Cancer Services - Coeur d'Alene

Coeur d'Alene, ID

Open and Accepting

Walter Knox Memorial Hospital

Emmett, ID

Open and Accepting

Saint Luke's Mountain States Tumor Institute (Fruitland)

Fruitland, ID

Open and Accepting

St. Luke's Cancer Institute (Meridian)

Meridian, ID

Open and Accepting

Idaho Urologic Institute

Meridian, ID

Open and Accepting

Saint Luke's Mountain States Tumor Institute (Nampa)

Nampa, ID

Open and Accepting

Saint Alphonsus Cancer Care Center (Nampa)

Nampa, ID

Open and Accepting

Kootenai Cancer Center

Post Falls, ID

Open and Accepting

Kootenai Clinic

Sandpoint, ID

Open and Accepting

Saint Luke's Mountain States Tumor Institute (Twin Falls)

Twin Falls, ID

Open and Accepting

Illinois

OSF Saint Anthony's Health

Alton, IL

Open and Accepting

Rush - Copley Medical Center

Aurora, IL

Open and Accepting

Advocate Good Shepherd Hospital

Barrington, IL

Open and Accepting

Illinois CancerCare (Bloomington)

Bloomington, IL

Open and Accepting

Loyola Center for Health at Burr Ridge

Burr Ridge, IL

Open and Accepting

Illinois CancerCare (Canton)

Canton, IL

Open and Accepting

Memorial Hospital of Carbondale

Carbondale, IL

Open and Accepting

SIH Cancer Institute

Carterville, IL

Open and Accepting

Illinois CancerCare (Carthage)

Carthage, IL

Open and Accepting

Centralia Oncology Clinic

Centralia, IL

Open and Accepting

Advocate Illinois Masonic Medical Center

Chicago, IL

Open and Accepting

John H. Stroger Jr. Hospital of Cook County

Chicago, IL

Open and Accepting

AMG Crystal Lake - Oncology

Crystal Lake, IL

Open and Accepting

Carle Foundation Hospital (Vermilion)

Danville, IL

Open and Accepting

Cancer Care Specialists of IL - Cancer Care Center of Decatur

Decatur, IL

Open and Accepting

Memorial Health - Decatur Memorial Hospital Memorial Health

Decatur, IL

Open and Accepting

Northwestern Medicine Cancer Center (Kishwaukee)

DeKalb, IL

Open and Accepting

Illinois CancerCare-Dixon

Dixon, IL

Open and Accepting

Advocate Good Samaritan Hospital

Downers Grove, IL

Open and Accepting

Carle (Effingham)

Effingham, IL

Open and Accepting

Cancer Care Specialists (Crossroads Cancer Center)

Effingham, IL

Open and Accepting

Advocate Sherman Hospital

Elgin, IL

Open and Accepting

Illinois CancerCare (Eureka)

Eureka, IL

Open and Accepting

Illinois CancerCare (Galesburg)

Galesburg, IL

Open and Accepting

Western Illinois Cancer Treatment Center

Galesburg, IL

Open and Accepting

Northwestern Medicine Cancer Center Delnor

Geneva, IL

Open and Accepting

Advocate South Suburban Hospital

Hazel Crest, IL

Open and Accepting

Loyola Medicine Homer Glen

Homer Glen, IL

Open and Accepting

Illinois CancerCare (Kewanee)

Kewanee, IL

Open and Accepting

Condell Memorial Hospital

Libertyville, IL

Open and Accepting

AMG Libertyville - Oncology

Libertyville, IL

Open and Accepting

Illinois CancerCare (Macomb)

Macomb, IL

Open and Accepting

Carle Foundation Hospital (Mattoon)

Mattoon, IL

Open and Accepting

Loyola University Medical Center Cardinal Bernardin Cancer Center

Maywood, IL

Open and Accepting

Marjorie Weinberg Cancer Center at Loyola-Gottlieb

Melrose Park, IL

Open and Accepting

Good Samaritan Regional Health Center

Mount Vernon, IL

Open and Accepting

HSHS Saint Elizabeth's Hospital

O'Fallon, IL

Open and Accepting

Cancer Care Center of O'Fallon

O'Fallon, IL

Open and Accepting

Advocate Christ Medical Center

Oak Lawn, IL

Open and Accepting

Loyola Center for Cancer Care and Research

Orland Park, IL

Open and Accepting

Illinois CancerCare - Fox River Cancer Center

Ottawa, IL

Open and Accepting

Advocate Lutheran General Hospital

Park Ridge, IL

Open and Accepting

Illinois CancerCare - Pekin

Pekin, IL

Open and Accepting

Illinois CancerCare - Peoria

Peoria, IL

Open and Accepting